Double-Filtration Plasmapheresis for the Treatment of Patients With Recalcitrant Atopic Dermatitis

Therapeutic Apheresis and Dialysis

Volumn 17, Issue 6, 2013, Pages 631-637

  Kim, Jin Young ^a   Park, Joon Seong ^a   Park, Jun Chul ^a   Kim, Myoung Eun ^a   Nahm, Dong Ho ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Atopic; Dermatitis; Immunoglobulin; Plasmapheresis

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; EOSINOPHIL CATIONIC PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PREDNISOLONE;

ADULT; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE FILTRATION PLASMAPHERESIS; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LOW DRUG DOSE; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; STANDARDIZED CLINICAL SEVERITY SCORING SYSTEM FOR ATOPIC DERMATITIS; TREATMENT OUTCOME;

ATOPIC; DERMATITIS; IMMUNOGLOBULIN; PLASMAPHERESIS;

ADULT; DERMATITIS, ATOPIC; FEMALE; HUMANS; IMMUNOGLOBULINS; MALE; PLASMAPHERESIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84890248095     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12047     Document Type: Article

References (25)

1. Akdis CA, Akdis M, Bieber T etal. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006;118:152-169.
2. Novak N, Bieber T, Leung DY. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol 2003;112(6 Suppl):S128-139.
3. Hanifin JM, Cooper KD, Ho VC etal. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines". J Am Acad Dermatol 2004;50:391-404.
4. Yokoyama H, Wada T, Zhang W, Yamaya H, Asaka M. Advances in apheresis therapy for glomerular diseases. Clin Exp Nephrol 2007;11:122-127.
5. Aswad MI, Tauber J, Baum J. Plasmapheresis treatment in patients with severe atopic keratoconjunctivitis. Ophthalmology 1988;95:444-447.
6. Kasperkiewicz M, Schmidt E, Frambach Y etal. Improvement of treatment-refractory atopic dermatitis by immunoadsorption: a pilot study. J Allergy Clin Immunol 2011;127:267-270.
7. Narita YM, Hirahara K, Mizukawa Y, Kano Y, Shiohara T. Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: is cytokine expression analysis useful in predicting its therapeutic efficacy? J Dermatol 2011;38:236-245.
8. Lyu RK, Chen WH, Hsieh ST. Plasma exchange versus double filtration plasmapheresis in the treatment of Guillain-Barre syndrome. Ther Apher 2002;6:163-166.
9. Liu JF, Wang WX, Xue J etal. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis. Ther Apher Dial 2010;14:153-160.
10. Ramunni A, De Robertis F, Brescia P etal. A case report of double filtration plasmapheresis in an acute episode of multiple sclerosis. Ther Apher Dial 2008;12:250-254.
11. Hatano Y, Katagiri K, Arakawa S, Umeki T, Takayasu S, Fujiwara S. Successful treatment by double-filtration plasmapheresis of a patient with bullous pemphigoid: effects in vivo on transcripts of several genes for chemokines and cytokines in peripheral blood mononuclear cells. Br J Dermatol 2003;148:573-579.
12. Liu LL, Li XL, Wang LN, Yao L, Fan QL, Li ZL. Successful treatment of patients with systemic lupus erythematosus complicated with autoimmune thyroid disease using double-filtration plasmapheresis: a retrospective study. J Clin Apher 2011;26:174-180.
13. Kasuya A, Moriki M, Tatsuno K, Hirakawa S, Tokura Y. Clearance efficacy of autoantibodies in double filtration plasmapheresis for pemphigus foliaceus. Acta Derm Venereol 2013;93:181-215.
14. Hanifin JM, Rajka G. Diagnostic features of atopic eczema. Acta Derm Venereol (Stockh) 1980;92 (Suppl):44-47.
15. European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Dermatology 1993;186:23-31.
16. Kaplan AA. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis 2008;52:1180-1196.
17. Venge P, Bystrom J, Carlson M etal. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy 1999;29:1172-1186.
18. Peterson CG, Venge P. Interaction and complex-formation between the eosinophil cationic protein and alpha 2-macroglobulin. Biochem J 1987;245:781-787.
19. Venge P. Monitoring the allergic inflammation. Allergy 2004;59:26-32.
20. Czech W, Krutmann J, Schopf E, Kapp A. Serum eosinophil cationic protein (ECP) is a sensitive measure for disease activity in atopic dermatitis. Br J Dermatol 1992;126:351-355.
21. Kato T, Kobayashi T, Nishino H, Hidaka Y. Double-filtration plasmapheresis for resolution of corticosteroid resistant adult onset Still's disease. Clin Rheumatol 2006;25:579-582.
22. Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006;54:68-72.
23. Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005;53:338-340.
24. Simon D, Hosli S, Kostylina G, Yawalkar N, Simon HU. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008;121:122-128.
25. Jiang X, Lu M, Ying Y, Feng J, Ye Y. A case report of double-filtration plasmapheresis for the resolution of refractory chronic urticaria. Ther Apher Dial 2008;12:505-508.